Abstract: A hydrogel layer is applied to a substrate advantageously when the layer is formed in situ, using a polymeric or copolymeric precursor that includes, respectively, monomer subunits that have a photocrosslinkable functionality and monomer subunits that have a chemically selective functionality for binding a biomolecular analyte, such as a protein. A hydrogel-coated substrate thus obtained is particularly useful as a probe for mass spectroscopic analysis, including SELDI analysis. Hydrogel particles also can be used for SELDI analysis.

Abstract: The present invention is directed to a blood clot filter for implantation in a patient comprising a blood clot filter having a coating comprising one or more pharmaceutically active compounds.

Abstract: Compositions and methods for occluding a vessel in a subject are provided in which a vaso-occlusion device includes an occluding element having a polymeric material containing a plurality of holes at least partially filled with one or more bioactive agents, the vaso-occlusion device configured to occlude a vessel in the subject.

Abstract: A reagent and related method for use in passivating a biomaterial surface, the reagent including a latent reactive group and a bifunctional aliphatic acid (e.g., fatty acid), in combination with a spacer group linking the latent reactive group to the aliphatic acid in a manner that preserves the desired function of each group. Once bound to the surface, via the latent reactive group, the reagent presents the aliphatic acid to the physiological environment, in vivo, in a manner (e.g., concentration and orientation) sufficient to hold and orient albumin.

Abstract: Supple tissue dressing assemblies are formed from hydrophilic polymer sponge structures, such as chitosan. The supple tissue dressing assemblies are characterized by suppleness or multi-dimensional flexibility. The assemblies can be flexed, bent, folded, twisted, and even rolled upon itself before and during use, without creasing, cracking, fracturing, otherwise compromising the integrity and mechanical and/or therapeutic characteristics of the assemblies.

Abstract: A tyrosinase activity inhibitor and an ameliorant for facial blood flow that are excellent in terms of safety, and medicinal compositions, food compositions, and cosmetic preparations that contain the inhibitor and the ameliorant as active ingredients are provided. A tyrosinase activity inhibitor and an ameliorant for facial blood flow that contain anthocyan obtained by concentration or extraction of plant material, and medicinal compositions, food compositions, and cosmetic preparations that have an inhibitory action on tyrosinase activity and ameliorating action on facial blood flow are provided.

Abstract: Methods for achieving weight loss goals and maintaining weight loss including selecting an appropriate weight loss program and identifying a weight loss goal, followed by participating in the weight loss program until the weight loss goal is achieved; then ending the weight loss program participation; and consuming an ingestible composition at regular intervals beginning from 1 day to about 7 days after ending the weight loss program, the ingestible composition comprising an effective amount of a multivalent cation and an effective amount of an soluble anionic fiber.

Abstract: A formed food or other ingestible composition having at least one soluble anionic fiber and at least one multivalent cation wherein the combination of fiber and cation increases viscosity of digesta. Methods of weight management including inducing satiety, reducing caloric intake, weight loss and improving weight loss, using the formed food or ingestible compositions having at least one soluble anionic fiber and at least one multivalent cation.

Abstract: An ingestible composition to increase viscosity imparted to the digesta in an intestine that includes a soluble anionic fiber and a protected cation. The protected cation may be coated with an enteric coating, a lipid coating, or a sustained release coating.

Abstract: Compositions and methods for inducing statiety and for reducing caloric intake having at least soluble anionic fiber and at least one soluble cation. The compositions may be solid, fluid, or mixtures thereof.

Abstract: Ingestible compositions that include one or more anionic soluble fibers are provided herein. An ingestible composition can be in solid or liquid form. In certain cases, a solid ingestible composition includes an extruded food product, such as a crispy, that includes one or more anionic soluble fibers. Liquid ingestible compositions that can include one or more alginate anionic soluble fibers and one or more pectin anionic soluble fibers are also provided. Methods for making ingestible compositions are provided, as well as methods for using the ingestible compositions, e.g., to induce satiety or to increase the viscosity of stomach contents.

Abstract: Ingestible compositions that include one or more anionic soluble fibers are provided herein. An ingestible composition can be in solid or liquid form. In certain cases, a solid ingestible composition includes an extruded food product, such as a crispy, that includes one or more anionic soluble fibers. Liquid ingestible compositions that can include one or more alginate anionic soluble fibers and one or more pectin anionic soluble fibers are also provided. Methods for making ingestible compositions are provided, as well as methods for using the ingestible compositions, e.g., to induce satiety or to increase the viscosity of stomach contents.

Abstract: The invention relates to relatively light and thermally stable granulated, fermentation-broth-based animal feed additives having a high content of L-lysine and to low-loss methods for their production from broths obtained by fermentation.

Abstract: The invention relates to a skin care pad comprising exfoliating elements (4) which are distributed between at least one first fibrous layer (2) and a second fibrous layer (6), said second layer having a lower basis weight than the first fibrous layer. In this way, the inventive pad can be used daily, in order to exfoliate and massage the skin and to remove make-up.

Abstract: Cleansing article of a textile that is impregnated with a preparation containing a) one or more anionic surfactants in a total concentration of from 1 to 30% ,by weight and b) one or more lipids liquid or viscous at room temperature in a total concentration of at least 8% by weight, respectively based on the total weight of the preparation, its production and use.

Abstract: A two sided cleansing wipe has a first side treated with a cleaner and a second side treated with a disinfectant. The wipe is used to first apply the cleaner to the surface of an object and thereafter apply a disinfectant. The first side may contain a color indicator to show the extent to which the surface has been cleaned. The indicator is removed during application of the disinfectant. The cleansing wipe finds use in cleaning and disinfecting medical equipment.

Abstract: Methods for maintaining a low vaginal pH, preventing the propagation of toxic shock syndrome toxin 1 production during menstruation, preventing the shedding and dissemination of a herpesvirus and treating herpes lesions comprising administering to a human a formulation comprising a pharmaceutically effective amount of an insoluble micronized form of cellulose acetate phthalate or a cellulose acetate phthalate film or a cellulose acetate phthalate porous sponge. Also a method of treating Candida albicans infection comprising administering to a human female a pharmaceutically effective amount of a composition comprising micronized cellulose acetate phthalate and miconazole nitrate.

Abstract: A wound care dressing is disclosed. The wound care dressing comprises a water-soluble nonwoven blanket in combination with a planar, non-water soluble wound care composition.

Abstract: It is intended to provide pergolide-containing transdermal preparations having reducreduced side effects and exerting sufficient therapeutic effects. Namely, a pergolide-containing transdermal preparation which is capable of achieving a plasma AUC ratio of pergolide or the like to at least one pergolide metabolite of 1:0.5 to 1:5; and/or transdermal preparation containing pergolide and/or a pharmaceutically acceptable salt thereof which is capable of achieving a ratio (A/B) of the maximum plasma level (A) of pergolide and/or a pharmaceutically acceptable salt thereof to the plasma level (B) thereof in the next administration of less than 2.

Abstract: A transdermal nicotine salt delivery system to an individual. The system has a high nicotine salt loading to effect therapeutic flux rate. Acrylate polymeric drug reservoir with the high nicotine salt dissolved therein provides desirable adhesive characteristics and effective transdermal therapeutic properties.

Abstract: The present invention provides a novel approach for the preparation of fatty alcohol esters of ?-hydroxy carboxylic acids. The present invention also provides a novel topical gel for the transdermal delivery of steroids using the fatty alcohol esters as permeation enhancers.

Abstract: The present invention provides a system for transdermal delivery of dried or lyophilized pharmaceutical compositions and methods using thereof. The system comprises an apparatus for facilitating transdermal delivery of a peptide or polypeptide that generates hydrophilic micro-channels, and a patch comprising dried therapeutically peptide or polypeptide. Particularly, the system of the present invention facilitates transdermal delivery of parathyroid hormone useful for preventing or treating bone disorders.

Abstract: The present invention provides pharmaceutical compositions for topical delivery comprising a suitable carrier and a codrug capable of penetrating, or being transported across, the dermis. The codrug according to the invention comprises a first constituent moiety linked to a second constituent moiety, wherein the second constituent moiety is the same as, or different from, the first constituent moiety. The first and second constituent moieties are so linked that they are easily transported into or across the dermis, into the skin, or into the blood or lymphatic system, and are reconstituted in vivo to form the first and second constituent moieties.

Abstract: Disclosed are multilayered liposomes for transdermal absorption and a method of preparing the liposomes. The multilayered liposomes are prepared using a mixture of oil-phase components comprising squalane, sterols, ceramides, neutral lipids or oils, fatty acids and lecithins, is 200 to 5000 nm in particle size, and is capable of entrapping a physiologically active substance. The multilayered liposomes entrap a larger amount of a physiologically active substance and are structurally stable when encapsulating the physiologically active substance, compared to unilamellar liposomes. Also, they are prepared by a simple and cost-effective process not using a high-pressure homogenizer but using a general homo mixer.

Abstract: The invention provides liposomal vehicles for encapsulating relatively high levels of water-soluble substances including immunogens directed against gastrin and gonadotropin releasing hormone. The liposome encapsulating large amounts of immunogens can be injected parentally to induce effective immune responses without exhibiting significant adverse tissue reactogenicity.

Abstract: The methods of the invention can be used to protect against lymphocyte DNA damage and free-radical associated disorders in a subject. The methods of the present invention can be used to increase the antioxidant capacity in both the aqueous and lipid compartments, decrease DNA oxidation, decrease lipid peroxidation, and increase antioxidant nutrient levels in the circulation. The protective effect of the physiologic dose of the mixed carotenoid supplement is rapid, consistent and cumulative.

Abstract: A seamless capsule manufacturing device comprises a multiple nozzle 7 for ejecting liquid drops into hardening liquid 10 and a flow passage tube 11 for containing hardening liquid 10. The flow passage tube 11 has a deformation section 28 that includes an inlet part 25 and a formation tube part 28b showing a cross sectional area smaller than the inlet part 25. The liquid drops ejected from the multiple nozzle 7 into the hardening liquid 10 are once made to become spherical liquid drops 26 in a sol state at the inlet part 25. The liquid drops 26b are introduced from the inlet part 25 into the deformation section 28 while they are still in a sol state. As hardening liquid 10 is introduced from the inlet part 25 into the formation tube part 28b, its flow rate is changed and the liquid drops 26 are deformed due to the change in the flow rate to produce nonspherical seamless capsules SC.

Abstract: An enteric valproic acid soft gelatin capsule, in which the enteric polymer is a component of the capsule shell rather than a coating, has been developed. The fill material comprises valproic acid or divalproex sodium and, optionally, one or more pharmaceutically acceptable excipients such as corn oil. The capsule shell is prepared from a mass comprising a film-forming polymer, an acid insoluble polymer, an aqueous solvent, and optionally a plasticizer. Suitable film-forming polymers include gelatin. Suitable acid-insoluble polymers include acrylic-acid/methacrylic acid copolymers. The acid-insoluble polymer is present in an amount from about 8% to about 20% by weight of the wet gel mass. The weight ratio of acid-insoluble polymer to film-forming polymer is from about 25% to about 50%. The aqueous solvent is water or an aqueous solution of alkalis such as ammonia or diethylene amine or hydroalcoholic solutions of the same. Suitable plasticizers include glycerin and triethylcitrate.

Abstract: A chewable tablet comprising a group which contains an acid-labile active ingredient and at least one basic substance selected from alkaline earth metal carbonate, metal oxide and metal hydroxide, and a group which does not contain an acid-labile active ingredient and contains at least one ingredient selected from alkaline earth metal carbonate, metal oxide and metal hydroxide, wherein said chewable tablet is capable of rapidly neutralizing gastric acid and is preferably not enteric-coated, is provided.

Abstract: Orally dissolvable dosage forms comprising sleep aids such as benodiazepines are described. The dosage forms may be in the form of tablets or strips. In certain embodiments, the dosage forms may comprise particles, granules, microgranules, or crystals, and a matrix. The particles, granules or microgranules comprise a combination of immediate-release particles, granules or microgranules with sustained-release, delayed-release or enteric-coated particles, granules or microgranules. In one embodiment, the sleep aid is diazepam, triazolam, midazolam, temazepam, flurazepam, zolpidem, zaleplon or a combination thereof. The sleep aids are typically employed in pharmaceutically effective amounts to treat insomnia.

Abstract: An extended release formulation for administration of venlafaxine in an oral tablet dosage form. The formulation preferably features a core, over which an outer coating is layered. The core preferably contains venlafaxine, a filler, and a water soluble cellulosic polymer, optionally and more preferably with a water insoluble cellulosic polymer. The core is preferably coated with a coating material. The coating preferably contains a mixture of water soluble cellulosic polymer and a water insoluble cellulosic polymer. According to a first embodiment of the present invention, the filler is preferably present in an amount of at least about 40% weight per weight of the total formulation. More preferably, the filler comprises microcrystalline cellulose. Most preferably, the filler solely comprises microcrystalline cellulose. Also most preferably, microcrystalline cellulose is present in the core in a range of from about 45% to about 65% weight per weight of the total formulation.

Abstract: Modified or extended release formulations containing propanolol compounds and associated methods are disclosed and described. In some aspects, such formulations may be substantially bioequivalent to known FDA approved propanolol formulations such as INDERAL LA®.

Abstract: Modified or extended release formulations containing propanolol compounds and associated methods are disclosed and described. In some aspects, such formulations may be substantially bioequivalent to known FDA approved propanolol formulations such as INDERAL LA®.

Abstract: The invention features methods of making hydrogel constructs that can be used to repair perforations in tympanic membranes, the hydrogel constructs themselves, and methods of repair.

Abstract: Solid dispersions of stable, amorphous opioid antagonists, particularly [[2(S)-[[4(R)-(3-hydroxyphenyl)-3(R),4-dimethyl-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]acetic acid, with improved water solubility and bioavailability are disclosed. Also disclosed are methods of preventing or treating a side effect associated with an opioid. In addition, methods of treating or preventing pain, ileus, and opioid bowel dysfunction are disclosed.

Abstract: The invention provides a method for reducing the average size of biologically active compound particles or agglomerates suspended in a fluid by flowing one or more times said fluid having biologically active compound particles or agglomerates suspended therein through one or more magnetic fields to reduce the average size of a substantial portion of the biologically active compound particles or agglomerates by at least 25%. This method may be incorporated into a process for manufacturing a 10 biologically active compound formulation.

Abstract: The invention encompasses sable candesartan cilexetil of fine particle size, wherein desethyl-candesartan (desethyl-CNS) within the stable candesartan cilexetil does not increase to more than about 0.1% w/w by HPLC relative to the initial amount of candesartan cilexetil, when the stable candesartan cilexetil is maintained at a temperature of about 55° C. for at least 2 weeks, methods of making the same and pharmaceutical compositions thereof.

Abstract: An antibiotic peptide is made by hydrolyzing milk protein. The hydrolysis is performed with a fungal protease in a single step at a protein concentration of 21 to 35 wt % to a DH of at least about 12%. The resulting antibiotic peptide has at least a log 2 kill of bacteria. It may be coated onto plants or animals or used in foods, medicines, ointment, or pastes.

Abstract: Tissue repair compositions, particularly bone repair compositions, containing demineralized bone fragments and homogenized connective tissues, and methods for making the same. The compositions can be used in the form of an injectable gel, an injectable paste, a paste, a putty, or a rehydratable freeze-dried form.

Abstract: Tissue repair compositions, particularly bone repair compositions, containing demineralized bone fragments and homogenized connective tissues. The compositions can be used in the form of an injectable gel, an injectable paste, a paste, a putty, or a rehydratable freeze-dried form.

Abstract: A method or producing a cross-linked collagenous biomaterial includes the step of providing a collagenous biomaterial and irradiating the collagenous biomaterial with gamma radiation at a dose of between about 20 and 160 kGy to produce the cross-linked collagenous biomaterial. The collagenous biomaterial is provided in the form of a gel and is produced by extracting bone powder or tendon.

Abstract: Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibrob-last Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.

Abstract: The present invention provides compositions for bowel cleansing that have improved palatability through the inclusion of a sweetener, such as a chlorinated sucrose isomer. The invention also provides methods of reducing the saltiness of an orally consumed substance, including phosphate salt and PEG/salt bowel cleansers, through the use of a sweetener. Utilizing a sweetener including Sucralose to reduce the saltiness of a substance unexpectedly contradicts the conventional belief that sweeteners amplify saltiness.

Abstract: Compositions useful in the prevention and treatment of osteoporosis and for bone and fracture repair. Slow-releasing calcium phosphate-based materials are disclosed, incorporating Mg, Zn, F and carbonate, which will promote bone formation and inhibit bone resorption and thus be agents for the cited uses.

Abstract: The present invention is directed to a variety of embodiments. For example, in at least one embodiment the invention is directed to formulations and methods for diagnosis of risk and for treatment to reduce this risk of upper gastrointestinal bleeding from erosions and ulcers. The compositions contain arachidonic acid, such as, but not limited to, arachidonate, 20:4n-6, and may include one or more forms of tocopherol, such as, but not limited to, alpha-, beta-, gamma-, delta- or mixtures thereof, anti-inflammatory lipids, such as, but not limited to, fish oil, DHA, gamma-linolenic acid, and may also include trace minerals required for superoxide dismutase production, such as, but not limited to, copper, zinc, and manganese.

Abstract: A nutritional or dietary supplement composition that promotes retinal health through the prevention and/or treatment of visual acuity loss by reducing the risk of developing age-related macular degeneration in persons with early age-related macular degeneration. The essential ingredients of the nutritional or dietary supplement composition are vitamin C, micronutrients and other antioxidants. The essential ingredients are provided in an oral dosage. The composition is taken in the form of one or two tablets or capsules daily.

Abstract: A composition and method for treating dry-eye syndrome and symptoms of vitreous opacities in a host comprising the oral administration of a composition which contains a pharmacologically effective amount of essential fatty acids, polar phospholipids, vitamins, minerals and dietary supplements.

Abstract: Zeaxanthin, a dietary carotenoid that occurs in very small quantities in corn, spinach, and other dietary sources, can reduce light hyper-sensitivity and various related conditions (such as migraine or other recurrent headaches) in people who suffer from it. Preferred dosages range from about 10 to about 100 mg per day, depending on the severity of condition, and the weight and medical status of the person. High dosages during an initial “buildup” dosing regimen can promote increased concentrations in the macula and lens, and lower dosages can then be used for maintenance purposes. Lutein may be able to achieve similar results, but because of certain molecular and cellular factors, zeaxanthin is preferable. Additional active agents (such as bilberry or other plant extracts, Vitamins C or E, zinc, etc.) can also be included or coadministered with any such formulations.

Abstract: Novel triazole compounds represented by Formula (1): (where A, A1, A2, A3, A4, A5, B, R11, W, X, Y and Z are as defined herein) in which the triazole is substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal, obesity and other diseases.

Abstract: An object of the present invention is to provide IL-8 production promoters derived from safe food materials and to provide immunostimulants or preventive or treating agents of infectious disease comprising the IL-8 production promoter. The present inventors have found that a composition comprising, as an active ingredient, at least one plant extract from peppermint, dokudami (houttuynia herb), or licorice promotes IL-8 production, and that a composition comprising, as an active ingredient, at least one compound selected from the group consisting of ?-humulene, ?-pinene, ?-pinene, and L-menthol promotes IL-8 production. These IL-8 production promoters can be used in foods and drinks supplemented with immunostimulants or preventive or treating agents of infectious disease.